Plant Cells as Pharmaceutical Factories
Häkkinen, Suvi T.
Miralpeix i Anglada, Bruna
MetadataShow full item record
Molecules derived from plants make up a sizeable proportion of the drugs currently available on the market. These include a number of secondary metabolite compounds the monetary value of which is very high. New pharmaceuticals often originate in nature. Approximately 50% of new drug entities against cancer or microbial infections are derived from plants or micro-organisms. However, these compounds are structurally often too complex to be economically manufactured by chemical synthesis, and frequently isolation from naturally grown or cultivated plants is not a sustainable option. Therefore the biotechnological production of high-value plant secondary metabolites in cultivated cells is potentially an attractive alternative. Compared to microbial systems eukaryotic organisms such as plants are far more complex, and our understanding of the metabolic pathways in plants and their regulation at the systems level has been rather poor until recently. However, metabolic engineering including advanced multigene transformation techniques and state-of-art metabolomics platforms has given us entirely new tools to exploit plants as Green Factories. Single step engineering may be successful on occasion but in complex pathways, intermediate gene interventions most often do not affect the end product accumulation. In this review we discuss recent developments towards elucidation of complex plant biosynthetic pathways and the production of a number of highvalue pharmaceuticals including paclitaxel, tropane, morphine and terpenoid indole alkaloids in plants and cell cultures.
Is part ofCurrent Pharmaceutical Design, 2013, vol. 19,núm. 31, p. 5640-5660
European research projects
Showing items related by title, author, creator and subject.
Miralpeix i Anglada, Bruna; Rischer, Heiko; Häkkinen, Suvi T.; Ritala, Anneli; Seppänen-Laakso, Tuulikki; Oksman-Caldentey, Kirsi-Marja; Capell Capell, Teresa; Christou, Paul (Bentham Science Publishers, 2013)Secondary products are small molecular weight compounds produced by secondary metabolic pathways in plants. They are re- garded as non-essential for normal growth and development but often confer benefits such as defense ...
Zorrilla López, Uxue; Masip Vilà, Gemma; Arjó Pont, Gemma; Bai, Chao; Banakar, Raviraj; Bassie Rene, Ludovic; Berman Quintana, Judit; Farré Martinez, Gemma; Miralpeix i Anglada, Bruna; Pérez Massot, Eduard; Sabalza Gallués, Maite; Sanahuja Solsona, Georgina; Vamvaka, Evangelia; Twyman, Richard M.; Christou, Paul; Zhu, Changfu; Capell Capell, Teresa (University of the Basque Country Press, 2013)Metabolic engineering in plants can be used to increase the abundance of specific valuable metabolites, but single-point interventions generally do not improve the yields of target metabolites unless that product is ...
Yuan, Dawei; Bassie Rene, Ludovic; Sabalza Gallués, Maite; Miralpeix i Anglada, Bruna; Dashevskaya, Svetlana; Farré Martinez, Gemma; Rivera Vélez, Sol Maiam; Banakar, Raviraj; Bai, Chao; Sanahuja Solsona, Georgina; Arjó Pont, Gemma; Avilla, Eva; Zorrilla López, Uxue; Ugidos-Damboriena, Nerea; López, Alberto; Almacellas, David; Zhu, Changfu; Capell Capell, Teresa; Hahne, Gunther; Twyman, Richard M.; Christou, Paul (Springer Verlag, 2011)The eight Millennium Development Goals (MDGs) are international development targets for the year 2015 that aim to achieve relative improvements in the standards of health, socioeconomic status and education in the ...